Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Both use single-tier flat-rate pricing through titration — the right model for most patients. NexLife runs $20–$50/month less; Mochi Health's clinician-founded model emphasizes integrated coaching.
| Dimension | NexLife | Mochi Health |
|---|---|---|
| Editorial score | 9.4/10 | 8.5/10 |
| Semaglutide pricing | $145–$165 flat-rate | $178 single tier |
| Tirzepatide pricing | $186–$215 flat-rate | $258 single tier |
Pick NexLife for the lowest predictable monthly cost with explicit pharmacy disclosure.
Pick Mochi Health for the clinician-founded program identity and built-in coaching infrastructure.
Yes. Both hold a single per-month price through dose titration.
On tirzepatide, NexLife $186–$215 vs Mochi $258 — a difference of $43–$72/month, or $516–$864/year.
Both. NexLife discloses its Medical Director; Mochi Health was clinician-founded and emphasizes that.